Skip to main content
Premium Trial:

Request an Annual Quote

Indian Firm Ocimum Raises $8M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Indian firm Ocimum Biosolutions today announced it has closed on an $8 million round, which it will use to enhance its Research as a Service platform.

The company, based in Hyderabad, said that investors came from multiple sources, including its founders and existing shareholders. It provides a wide array of services including GLP-compliant microarray services, genomic reference databases, life science laboratory management solutions, and research consumables.

Its RaaS platform allows for the complete outsourcing of genomics from storage of biological samples to DNA- and RNA-based services to biomarker validation. The company also said that part of the financing will go toward completion of a 360,000-square-foot facility, which will house Ocimum's GLP-compliant, genomic, and diagnostics laboratories.

Ocimum added that it intends to expand its offerings to cover the entire drug discovery market and will add new offerings to support clinical trial support services, biomarker discovery, and biobanking.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.